Validation data for LPS-EB Vaccigrade™

https://www.invivogen.com/lpseb-vaccigrade

For research use only

Version 23H21-AK

LPS-EB is a preparation of a smooth (s)-form of lipopolysaccharide (LPS) purified from the Gram-negative *E. coli* 0111:B4, a pathogenic serotype of *E. coli* known to cause significant gastric disease. LPS-EB Vaccigrade^{M} is extracted by successive enzymatic hydrolysis steps and purified by the previously described phenol-TEA-DOC extraction protocol. This process removes contaminating lipoproteins. Therefore, LPS-EB Vaccigrade^{M} only activates TLR4, as verified using InvivoGen's HEK-Blue^{M} hTLR2 and HEK-Blue^{M} hTLR4 cells (**Figure 1**).

Dose-dependent response of TLR2 and TLR4




Figure 1. LPS-EB VaccigradeTM is a potent activator of human (h)TLR4. The cells were incubated with increasing concentrations of LPS-EB VaccigradeTM. After overnight incubation in HEK-BlueTM detection medium, a SEAP detection growth medium, the response of hTLR2 and hTLR4 was assessed by determining the presence of SEAP in the supernatant. Data are expressed as optical density at 630 nm (\pm SEM).

Note: 1 mg/ml corresponds to 1 x 10⁶ EU/ml.

